Investor Alert: Cidara Therapeutics Under Investigation; Rosen Law Firm Encourages Shareholders to Seek Counsel

Rosen Law Firm, a globally recognized investor rights law firm, has issued a notice to investors holding shares of Cidara Therapeutics, Inc. CDTX, a San Diego-based biotechnology company dedicated to the discovery and development of novel long-acting anti-infectives. The firm is calling on CDTX shareholders to inquire about a potential securities class action lawsuit.

Grounds for the Investigation

The investigation by Rosen Law Firm seeks to determine whether Cidara Therapeutics may have issued misleading business information to the investing public, thus potentially violating securities laws. Investors who have been affected are encouraged to join the class action to recover their losses. Represented by the top ranked investor counsel, Rosen aims to ensure the company's management and board of directors are held accountable for their actions if they have negatively impacted shareholder value.

About Cidara Therapeutics Inc.

CDTX is engaged in a critical sector, with their biotechnological advancements aimed at preventing and treating diseases. Based in San Diego, California, Cidara Therapeutics is at the forefront of tackling some of the most challenging diseases through their innovative anti-infective treatments. This news of a potential investigation places a spotlight on the governance and disclosure practices of the company.

Investor Participation Encouraged

Rosen Law Firm advises CDTX investors to act swiftly and seek legal consultation. Investors are potentially eligible to recover their investment losses and may play a role in the judicial process to secure a favorable outcome. The firm's track record and proficiency in investor representation bolster confidence for CDTX shareholders considering participation in the class action lawsuit.

Investor, Lawsuit, Biotech